

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



常茂生物化學工程股份有限公司

Changmao Biochemical Engineering Company Limited*

(a joint stock limited company incorporated in the People's Republic of China)

(Stock Code: 954)

PROFIT WARNING

This announcement is made by Changmao Biochemical Engineering Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the profit warning announcements of the Company dated 19 April 2017 and 20 July 2017 (the “**Previous Announcements**”). Unless otherwise defined, capitalised terms used herein shall have the same meaning as those defined in the Previous Announcements.

The board of directors of the Company (the “**Board**”) wishes to inform the shareholders of the Company and potential investors that having assessed the currently available information, although there is an estimated increase in the Group's revenue for the year ended 31 December 2017, the Group is likely to record a significant decline in the consolidated net profits for the year ended 31 December 2017 as compared with the consolidated net profits for the year ended 31 December 2016.

As mentioned in the Previous Announcements, the Board believes that the Group's financial performance for the year ended 31 December 2017 has been affected mainly by:

- (i) the drop of profit margin of its products resulted from the significant increase in raw material price during the year ended 31 December 2017 as compared to that in the corresponding period in 2016; and

**For identification purpose*

- (ii) the transformation of its maleic anhydride production lines with an annual production capacity of 20,000 tons in its Changzhou plant (the “**Transformation**”) which was commenced in March 2017. Upon completion of the Transformation, butane instead of benzene will be used as a raw material to manufacture maleic anhydride. During the period of the Transformation, the production of maleic anhydride, a major raw material for the production of other major products of the Group, had to be temporarily suspended and the Group had to source maleic anhydride from external suppliers and incurred extra energy costs such as steam cost and other manufacturing costs. Steam was a side product of the maleic anhydride production lines which was previously recycled for production of other products before the suspension. The Board considers that despite the adverse financial impact resulted from the temporary increase in production costs in the short-run, the Transformation is expected to have a cost saving advantage in the long run. The construction work of the Transformation has been completed in the fourth quarter of 2017 and is currently under trial run. It is expected that the production will be in full operation in the first half of 2018.

As the Company is still in the process of finalising its results of the Group for the year ended 31 December 2017, the information contained in this announcement is a preliminary assessment by the Board with reference to the management accounts of the Group and the information currently available to the Company. Such information has not been audited or reviewed by the Company’s auditor and/or the audit committee. Further details of the Group’s performance will be disclosed when the Group’s results for the year ended 31 December 2017 are announced.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Changmao Biochemical Engineering Company Limited*
Rui Xin Sheng
Chairman

The PRC, 9 February 2018

As at the date hereof, Mr. Rui Xin Sheng (Chairman) and Mr. Pan Chun are the executive directors of the Company, Mr. Zeng Xian Biao, Mr. Yu Xiao Ping, Mr. Wang Jian Ping and Ms. Leng Yi Xin are the non-executive directors of the Company, Prof. Ouyang Ping Kai, Prof. Yang Sheng Li, Ms. Wei Xin and Ms. Au Fung Lan are the independent non-executive directors of the Company.

**For identification purpose*